RE:RE:IBD update ... market sizeNick80 wrote: that is very positive indeed, however our potential IBD drug is many years away from being relevant and to be come relevant it has to pass so many hurdles. I cant imagine how many raises and interviews and trails are necessary to bring this forward... and one event can kill it on the track.
I am desperate for some good news to but that ain't good enough.I didn't come to terms being overextended in this risky play and still have to digest what happend to ate 346 which gave me a negative return of 80% of my investment just because I was to hopeful.
This might well be 90 to 95% soon and I really hope not.
Nick - please forgive - but I don't look at share price as an indicator (unless I'm selling).
That being said ... the question really is ... is there anything of value here?
That's for everyone to decide on their own - no one can make that decisions for you.
As far as I'm concerned, I look at OTENA as being in a very unique and interesting place. GI safety and CV saftely are right where we want it. Has OTENA failed? No. What it's guilty of ... is ... not knowing where the bottom dose is. Once we know where the bottom is - then we'll be told the path forward ... low-dose, high-dose or both options (IMO).
In parallel, we need to build a drug pipeline and that's where IBD comes in. Forget how far it is in the future but cash today will help them build the pipeline of tomorrow. Gotta start somewhere and gotta start yesterday.
If I get what I'm looking for ... I'm going to get a more improved OTENA - future replacement for OTENA - future 340 replacement at 20 year IPs - and - an IBD drug that can rock this world, way beyond IBD indications. These are all valuable w.r.t negotiations over the next 5 years IMO.
What I'm saying is ... if you want a chance at being acquired as a business ... for a very nice valuation (one day) ... you have to build that company with many parallel opportunities. That's where you reduce risk.
Sure ... one step at a time ... we need October's update. But in the meantime ... you build a much larger organization with a drug development funnel. Afterall ... that's what ATE is supposed to become - a drug creation powerhouse.
That's why I'm here and I like that strategy.